Hottest Stocks (Over $10)	Hottest Stocks ($2-$10)	Biggest Losers (Over $10)	Biggest Losers ($2-$10)	Hottest Industries	Hottest Sectors	EPS / Sales Surprises
Enter Ticker Symbol:   Ticker Lookup Company Quote Company Profile Research Summary EPS Consensus Perspective Insider Transactions Price Performance

Enter any portion of the company’s name to find its corresponding ticker symbol:

Search for :

Zacks Company Profile for Integrated BioPharma Inc. (INBP : OTC)

• Company Description    Integrated BioPharma, Inc. is a well-established biopharma company serving the varied needs of the nutraceutical, biotech and pharmaceutical industries. Through a number of wholly owned subsidiaries INB develops, manufactures and distributes, worldwide over 130 products. Number of Employees: 153

• Price / Volume Information    Yesterday's Closing Price: $0.31 Daily Weekly Monthly 20 Day Moving Average: 5,352 shares Shares Outstanding: 30.98 (millions) Market Capitalization: $9.60 (millions) Beta: 0.95 52 Week High: $0.42 52 Week Low: $0.22 Short Interest Ratio:   % Price Change % Price Change Relative to S&P 500 4 Week 0.00% -2.62% 12 Week 16.41% 11.58% Year To Date -5.98% -17.81%

• Address & Contact Information Street Address Phone / Fax Email Address Web URL 225 LONG AVENUE BUILDING 15 - HILLSIDE,NJ 07205 USA ph: 888-319-6962 fax: 973-926-1735 investors@ibiopharma.com http://www.ibiopharma.com

• General Corporate Information    Officers Christina Kay - Co-Chief Executive Officer and Director Riva Sheppard - Co-Chief Executive Officer and Director Dina L. Masi - Chief Financial Officer Robert Canarick - Director Damon DeSantis - Director Peer Information Integrated BioPharma Inc. (GSAC) Integrated BioPharma Inc. (CASI) Integrated BioPharma Inc. (ALCD.) Integrated BioPharma Inc. (OMNN) Integrated BioPharma Inc. (CGPI.) Integrated BioPharma Inc. (CATX) Industry / Sector / Ticker Info Analyst Coverage: No Industry Group: MED-DRUGS Sector: Medical CUSIP: 45811V105 SIC: 2834 Fiscal Year Fiscal Year End: June Last Reported Quarter: 06/01/25 Next Expected EPS Date: 11/12/25 Share - Related Items Shares Outstanding: 30.98 Most Recent Split Date: (:1) Beta: 0.95 Market Capitalization: $9.60 (millions)

• EPS Information     • Dividend Information Analyst Coverage: No Dividend Yield: 0.00% Current Fiscal Quarter EPS Consensus Estimate: $ Indicated Annual Dividend: $0.00 Current Fiscal Year EPS Consensus Estimate: $ Payout Ratio: 0.00 Number of Estimates in the Fiscal Year Consensus: Change In Payout Ratio: 0.00 Estmated Long-Term EPS Growth Rate: % Last Dividend Paid: NA - $0.00 Next EPS Report Date: 11/12/25

• Fundamental Ratios P/E Current FY Estimate: - Trailing 12 Months: 15.50 PEG Ratio: - Price Ratios Price/Book: 0.47 Price/Cash Flow: 4.62 Price / Sales: 0.18 EPS Growth vs. Year Ago Period: -200.00% vs. Previous Quarter: -150.00% Sales Growth vs. Year Ago Period: 11.21% vs. Previous Quarter: 1.63% ROE 09/30/25 - - 06/30/25 - 4.04 03/31/25 - 6.36 ROA 09/30/25 - - 06/30/25 - 3.16 03/31/25 - 4.84 Current Ratio 09/30/25 - - 06/30/25 - 4.42 03/31/25 - 3.72 Quick Ratio 09/30/25 - - 06/30/25 - 2.21 03/31/25 - 1.70 Operating Margin 09/30/25 - - 06/30/25 - 1.49 03/31/25 - 2.37 Net Margin 09/30/25 - - 06/30/25 - 1.49 03/31/25 - 2.37 Pre-Tax Margin 09/30/25 - - 06/30/25 - 3.79 03/31/25 - 3.55 Book Value 09/30/25 - - 06/30/25 - 0.66 03/31/25 - 0.67 Inventory Turnover 09/30/25 - - 06/30/25 - 4.68 03/31/25 - 4.36 Debt-to-Equity 09/30/25 - - 06/30/25 - 0.01 03/31/25 - 0.00 Debt-to-Capital 09/30/25 - - 06/30/25 - 0.56 03/31/25 - 0.17

Powered by Zacks Investment Research ©